Recent studies have provided compelling evidence for the efficacy of co-delivering siRNA targeting the interleukin 17 receptor B (IL17RB) gene alongside the chemotherapeutic agent doxorubicin (DOX) using nanoparticles in the context of BC treatment. The gene discussed is IL17RB; the disease is breast cancer.